EPI-743 in Friedreich's Ataxia Point Mutations

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations

Clinical Trial Description

The primary objective of this study is to investigate whether treatment with EPI-743 has a discernible impact on visual function—including visual acuity, visual fields and color vision as well as on any of a number of functional and subject/clinician-rated scales relevant in the treatment of Friedreich's ataxia, and to determine the safety of treatment with EPI-743. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01962363
Study type	Interventional
Source	University of South Florida
Contact
Status	Completed
Phase	Phase 2
Start date	October 2013
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02660112` - (+) Epicatechin to Treat Friedreich's Ataxia	Phase 2
Recruiting	`NCT02497534` - Biomarkers in Friedreich's Ataxia
Completed	`NCT04102501` - A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia	Phase 3
Completed	`NCT02179333` - Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
Completed	`NCT01016366` - Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia	Phase 2
Recruiting	`NCT02069509` - Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Terminated	`NCT00803868` - Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia	Phase 2/Phase 3
Completed	`NCT02797080` - Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia	Phase 3
Completed	`NCT02415127` - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia	Phase 3
Completed	`NCT00897221` - A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT02840669` - A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)	N/A
Completed	`NCT00697073` - Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients	Phase 3
Recruiting	`NCT02316314` - Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Completed	`NCT00631202` - Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT01728064` - Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT02593773` - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study	Phase 3
Completed	`NCT01035671` - Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia	Phase 2
Completed	`NCT00811681` - Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	Phase 3
Completed	`NCT00537680` - Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia	Phase 3
Completed	`NCT02445794` - A First in Human Study of RT001 in Patients With Friedreich's Ataxia	Phase 1/Phase 2